Quanta Pharma IGF-1 LR3 1mg

Quanta Pharma IGF-1 LR3 Research Benefits

• Muscle hyperplasia: Researched extensively for its role in stimulating the formation of new muscle cells rather than simply enlarging existing ones
• Extended bioactivity: Modified R3 structure reduces binding to IGF binding proteins, extending active half-life from minutes to over 20 hours compared to native IGF-1
• Cellular proliferation: Investigated for promoting satellite cell activation, differentiation, and skeletal muscle fibre recruitment
• Nutrient partitioning: Studied for its effect on directing nutrients preferentially toward muscle tissue rather than adipose storage
• Anti-catabolic action: Shown in research to reduce protein breakdown and support a net anabolic environment at the cellular level
• Neural and collagen support: Explored for potential roles in nerve repair, cartilage regeneration, and connective tissue remodelling

How Quanta Pharma IGF-1 LR3 Works

IGF-1 LR3 (Long R3 Insulin-like Growth Factor 1) is a synthetic 83 amino acid analogue of the naturally occurring IGF-1 peptide. The “LR3” modification consists of a 13 amino acid N-terminal extension combined with a single arginine-for-glutamic-acid substitution at position 3. This structural change dramatically reduces its affinity for IGF binding proteins (IGFBPs), allowing it to remain active in circulation far longer than its native counterpart.

Whereas endogenous IGF-1 has a circulating half-life measured in minutes, Quanta Pharma IGF-1 LR3 remains bioactive for approximately 20 to 30 hours. Research indicates it binds to the IGF-1 receptor with similar affinity to native IGF-1 but delivers a sustained, more potent signalling effect. This makes it a key research tool in studies of hyperplastic muscle growth, anabolic signalling cascades (PI3K/Akt/mTOR), and cellular differentiation.

Additionally, Quanta Pharma IGF-1 LR3 has been investigated for its effects on nutrient partitioning, insulin sensitivity, collagen synthesis, and satellite cell recruitment, making it one of the most versatile peptides in anabolic and regenerative research protocols.

Quanta Pharma IGF-1 LR3 vs Native IGF-1

While native IGF-1 and IGF-1 LR3 share the same receptor target, the LR3 modification produces a profoundly different research profile. Native IGF-1 is rapidly sequestered by IGFBPs and cleared from circulation within minutes, limiting its usefulness in practical research applications. Quanta Pharma IGF-1 LR3, by contrast, maintains bioactivity for roughly a full day per administration, allowing researchers to observe sustained receptor-mediated effects with stable, predictable pharmacokinetics. This extended window is why LR3 has become the preferred analogue in skeletal muscle and tissue regeneration studies.

Why Choose Quanta Pharma IGF-1 LR3?

Quanta Pharma is renowned for producing pharmaceutical-grade peptides with exceptional purity and accurate dosing. The 1mg vial of Quanta Pharma IGF-1 LR3 has been independently verified by Analiza Białek, one of Europe’s most respected analytical laboratories, with confirmed content of 1.07mg against a 1mg label claim and 98% purity on the finished product. Combined with pharmaceutical-grade lyophilisation, precise fill accuracy, and UK-based stock for fast dispatch, it is the confident choice for serious researchers.